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Letter to the Editor: Classification of Pituitary Adenomas 
T. Mindermann 
Department of Neurosurgery, University Hospitals Basel, Basel, Switzerland 
In their article, Sanno et al. [15] address an impor- 
tant issue concerning the classification of pituitary 
adenomas. Their proposed classification is based on 
the tumour's histological data. Yet, pituitary adeno- 
mas are treated by a number of specialists, not all of 
whom have histological data available. Therefore, I 
would like to present an alternative classification 
scheme which can be shared by endocrinologists, 
gynaecologists, ophthalmologists, neurosurgeons, 
pathologists, and researchers alike. 
Advances in the understanding of an adenoma's 
hormone synthesis (genotype), hormone storage 
(immunophenotype), and hormone release into the 
blood stream (clinical phenotype) have lead to sever- 
al parallel and sometimes confusing classifications of 
pituitary adenomas. The present confusion on what 
exactly is, e.g., a prolactinoma or a corticotroph cell 
adenoma (does it produce, store, or release ACTH?) 
has lead to the occasional use of such terms as "PRL- 
oma", "GH-oma", "ACTH-oma", and "TSH-oma" [2, 
16] or "somatotropinoma" nd "corticotropinoma" 
[3]. Unfortunately these terms do not clarify whether 
in the case of "PRL-omas" the adenomatous cells pro- 
duce, store, or release PRL or if the excessive release 
of PRL is caused by the stalk effect or raised intrasel- 
lar pressure which would mean that the adenomatous 
cells do not even derive from the mammotroph cell 
line. Cunently, due to these difficulties and to overlap 
created by the various terminologies, tumours of the 
same cell line may be classified ifferently depending 
on whether one refers to their genotype, immuno- 
phenotype, or clinical phenotype. Vice versa, tumours 
deriving from different cell lines may incorrectly be 
classified as identical tumours. In an attempt to over- 
come the difficulties in making a correct diagnosis 
based on clinical data, some authors have developed 
regression equations in order to extract most informa- 
tion from the clinical data [5]. The introduction of 
mathematical tools to improve the accuracy of the 
clinical diagnosis demonstrates the great difficulties 
encountered when trying to determine an adenoma's 
true nature in the absence of histological data. On the 
other hand, classifications based on a tumour's histo- 
logical examination can often not be shared with cli- 
nicians who treat their patients before or without sur- 
gery. 
Therefore, I would like to emphasize an unequivo- 
cal classification of the various adenoma types by 
crossreferencing an adenoma's cell line of origin, its 
immunoreactivity, and its clinical phenotype. At the 
same time, existing anatomical classifications should 
be used to complement this classification. The aim is 
to come to a diagnosis that can be shared by research- 
ers, pathologists, and clinicians. 
Proposed Classification of Pituitary Adenomas 
The system is based on the work by Kovacs [8] and 
Landolt [9] whose contributions replaced the classical 
histological designation of pituitary adenomas as 
acidophilic, basophilic, and chromophobic with the 
more meaningful designation as adenomas of a cer- 
tain anterior lobe cell line. It takes into account new 
findings that link somatotroph, mixed mammotroph 
and somatotroph, and mammosomatotroph adenomas 
to one basic cell line committed to the production of 
growth hormone [12]. 
The classification presented in Table 1 has been 
published elsewhere [18]. It takes into account an 
adenoma's direct and indirect (stalk effect, raised 
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T. Mindermann: Classification fPituitary Adenomas 
intrasellar pressure) endocrine activities. The direct 
endocrine activities are: hormone synthesis (geno- 
type), hormone storage (immunophenotype), and hor- 
mone release (clinical phenotype). The indirect endo- 
crine activities are: compression of non-adenomatous 
anterior lobe tissue resulting in partial pituitary insuf- 
ficiency and excessive release of PRL by non-ade- 
nomatous cells caused by the stalk effect or raised 
intrasellar pressure. 
The genotype is determined by molecular genetic 
techniques like in-situ hybridization [13] allowing 
one to identify both DNA and mRNA in adenomatous 
cells revealing their genetic fingerprint. It is the most 
accurate information obtainable concerning the cell 
line of origin and is mostly used in research. 
The immunophenotype is determined by the 
tumour's immunostaining properties when adenoma- 
tous tissue is stained with antibodies to the various 
anterior lobe hormones or hormonal compounds uch 
as the alpha-subunit. This technique reveals which 
hormone(s) or hormonal compound(s) are stored by 
tumorous cells. It is a less accurate way of determin- 
ing an adenoma's cell line of origin since hormonal 
products may be released without the delay of tissue 
storage. Immunostaining for the various anterior lobe 
hormones hould be part of today's routine diagnostic 
procedures. 
The clinical phenotype is the least accurate infor- 
mation concerning the nature of a pituitary adenoma 
because: (a) hormone excess may be insufficient o 
cause any clinical symptoms or signs, (b) release of 
hormonal products may be clinically silent, (c) due to 
raised intrasellar pressure or the stalk effect prolactin 
may be released in sufficient amounts to cause ame- 
norrhea and galactorrhea even though the tumour 
might not produce prolactin [1, 10, 11], (d) the clini- 
cal phenotype may be determined by only one of mul- 
tiple co-existing tumours of differing immunopheno- 
types [7], (e) tumours may change clinical and immu- 
nophenotype [14], and (f) in addition to hormone 
excess, tumours may cause partial pituitary insuffi- 
ciency. 
The proposed classification scheme keeps the doc- 
tor aware of the degree of certainty concerning the 
true nature of a pituitary adenoma. For obvious rea- 
sons, a classification of a patient's adenoma based on 
clinical data only leads to the least reliable diagnosis. 
One might grade the three groups represented in the 
three columns to which a pituitary adenoma may be 
designated as fair evidence (clinical phenotype), good 
269 
evidence (immunophenotype), or best evidence (cell 
line) for the correct diagnosis. 
The anatomical classification schemes developed 
by Hardy [4] and modified by Wilson [17] grade the 
tumour's extent of sellar destruction and its extrasel- 
lar extension. A newly developed classification by 
Knosp et al. [6] based on magnetic resonance imaging 
(MRI) grades an adenoma's invasion into the cavern- 
ous sinus space. At surgery, tumour extending beyond 
the intercarotid line in coronal MRI proved very like- 
ly to be associated with invasion [6]. These purely 
anatomical classifications should be used in addition 
since the data contained in these schemes have prog- 
nostic value and are helpful in choosing the best treat- 
ment. 
The proposed classification in combination with 
the various grading schemes hould facilitate interdis- 
ciplinary and interinstitutional communication on 
what tumour exactly clinicians, pathologists, differ- 
ent institutions and articles in scientific publications 
are referring to. It is designed to highten the aware- 
ness that there are several aspects characterizing a 
pituitary adenoma ranging from its cell line of origin 
to its immunophenotype and to its clinical presenta- 
tion. A hightened awareness of such aspects may help 
in improving study designs and in the understanding 
of the tumour biology and the clinical course of the 
various adenoma types. 
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